A clinical trial reveals Wegovy, a weight-loss drug, effectively reduced liver inflammation in a majority of patients with MASH, a serious liver disease. Around 63% of patients on semaglutide (Wegovy's active ingredient) saw improvement, compared to 34.3% on a placebo. While gastrointestinal side effects were common, the drug was generally well-tolerated.
